Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free ERNA Stock Alerts

Ernexa Therapeutics (ERNA) Competitors

Ernexa Therapeutics logo
$3.99 +0.25 (+6.68%)
Closing price 03:58 PM Eastern
Extended Trading
$4.00 +0.01 (+0.38%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ERNA vs. ALLR, QNTM, VYNE, LGVN, and KZIA

Should you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Allarity Therapeutics (ALLR), Quantum Biopharma (QNTM), VYNE Therapeutics (VYNE), Longeveron (LGVN), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry.

How does Ernexa Therapeutics compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Allarity Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Allarity Therapeutics' return on equity of -85.29% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allarity TherapeuticsN/A -85.29% -49.92%
Ernexa Therapeutics N/A -1,262.77%-228.54%

Allarity Therapeutics presently has a consensus price target of $9.75, suggesting a potential upside of 596.43%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Ernexa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allarity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ernexa Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 4 mentions for Ernexa Therapeutics and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.49 beat Ernexa Therapeutics' score of -0.50 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allarity Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ernexa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Allarity Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allarity Therapeutics$320K67.64-$11.23M-$0.80N/A
Ernexa Therapeutics$580K8.05-$14.08M-$3.02N/A

Summary

Allarity Therapeutics beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Quantum Biopharma?

Ernexa Therapeutics (NASDAQ:ERNA) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Ernexa Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Ernexa Therapeutics has higher revenue and earnings than Quantum Biopharma. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K8.05-$14.08M-$3.02N/A
Quantum BiopharmaN/AN/A-$26.17M-$8.72N/A

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for Ernexa Therapeutics and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.27 beat Ernexa Therapeutics' score of -0.50 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ernexa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Quantum Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Quantum Biopharma's return on equity of -436.23% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ernexa TherapeuticsN/A -1,262.77% -228.54%
Quantum Biopharma N/A -436.23%-150.85%

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 4.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ernexa Therapeutics beats Quantum Biopharma on 7 of the 11 factors compared between the two stocks.

How does Ernexa Therapeutics compare to VYNE Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Ernexa Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,646.14%. VYNE Therapeutics' return on equity of -74.86% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ernexa TherapeuticsN/A -1,262.77% -228.54%
VYNE Therapeutics -4,646.14%-74.86%-63.87%

Ernexa Therapeutics has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500.

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 4.5% of Ernexa Therapeutics shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ernexa Therapeutics has higher revenue and earnings than VYNE Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K8.05-$14.08M-$3.02N/A
VYNE Therapeutics$570K38.94-$26.48M-$0.78N/A

In the previous week, Ernexa Therapeutics had 4 more articles in the media than VYNE Therapeutics. MarketBeat recorded 4 mentions for Ernexa Therapeutics and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 0.00 beat Ernexa Therapeutics' score of -0.50 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ernexa Therapeutics Negative
VYNE Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

VYNE Therapeutics beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Longeveron?

Longeveron (NASDAQ:LGVN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Longeveron had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 5 mentions for Longeveron and 4 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of -0.50 beat Longeveron's score of -0.67 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
Ernexa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ernexa Therapeutics has lower revenue, but higher earnings than Longeveron. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longeveron$1.20M16.61-$22.70M-$1.28N/A
Ernexa Therapeutics$580K8.05-$14.08M-$3.02N/A

Ernexa Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,893.58%. Longeveron's return on equity of -199.79% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Longeveron-1,893.58% -199.79% -143.21%
Ernexa Therapeutics N/A -1,262.77%-228.54%

Longeveron has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Longeveron currently has a consensus target price of $5.50, suggesting a potential upside of 542.45%. Given Longeveron's stronger consensus rating and higher possible upside, research analysts clearly believe Longeveron is more favorable than Ernexa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longeveron
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Ernexa Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Longeveron beats Ernexa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Novogen. MarketBeat recorded 4 mentions for Ernexa Therapeutics and 1 mentions for Novogen. Ernexa Therapeutics' average media sentiment score of -0.50 beat Novogen's score of -1.32 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Ernexa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

30.9% of Novogen shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novogen has higher earnings, but lower revenue than Ernexa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novogen$30K739.75-$13.41MN/AN/A
Ernexa Therapeutics$580K8.05-$14.08M-$3.02N/A

Novogen's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovogenN/A N/A N/A
Ernexa Therapeutics N/A -1,262.77%-228.54%

Novogen has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Novogen currently has a consensus target price of $21.00, suggesting a potential upside of 56.13%. Given Novogen's stronger consensus rating and higher possible upside, research analysts clearly believe Novogen is more favorable than Ernexa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Ernexa Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Novogen beats Ernexa Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERNA vs. The Competition

Export
MetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.36M$3.09B$6.25B$11.77B
Dividend YieldN/A1.92%2.74%5.26%
P/E Ratio-0.0518.3729.2527.07
Price / Sales8.05278.28504.6873.43
Price / CashN/A55.2543.3053.90
Price / Book0.524.309.676.69
Net Income-$14.08M$72.19M$3.55B$332.64M
7 Day Performance-16.35%2.03%1.70%2.01%
1 Month Performance-20.40%6.42%5.62%9.19%
1 Year Performance-94.63%37.74%34.42%39.59%

Ernexa Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERNA
Ernexa Therapeutics
0.4443 of 5 stars		$3.99
+6.7%		N/AN/A$4.36M$580KN/A10
ALLR
Allarity Therapeutics
2.5317 of 5 stars		$1.38
+0.7%		$9.75
+606.5%		N/A$21.83M$320KN/A10
QNTM
Quantum Biopharma
0.5987 of 5 stars		$5.65
+5.2%		N/AN/A$21.58MN/AN/AN/A
VYNE
VYNE Therapeutics
0.9008 of 5 stars		$0.64
-0.6%		N/AN/A$21.19M$570KN/A30
LGVN
Longeveron
1.4353 of 5 stars		$0.87
-2.1%		$3.00
+246.6%		N/A$20.57M$1.20MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel